More than 100 medications have been linked to drug-induced lupus, but a handful of drugs account for most cases. The highest-risk medications are procainamide (a heart rhythm drug) and hydralazine (a blood pressure drug), which together have historically caused the majority of diagnosed cases. Today, biologic medications used for autoimmune conditions and cancer are an increasingly recognized trigger.
Drug-induced lupus produces symptoms similar to the autoimmune disease systemic lupus (SLE), including joint pain, fatigue, and skin rashes. The critical difference: it typically resolves after you stop taking the medication that caused it.
Highest-Risk Medications
Two older drugs carry the greatest risk by a wide margin. Procainamide, used to treat irregular heart rhythms, causes drug-induced lupus in roughly 20% of patients per year of use. Hydralazine, prescribed for high blood pressure, triggers it in 5% to 8% of patients per year. Both drugs are prescribed far less often today than they once were, which has shifted the overall landscape of drug-induced lupus toward newer medications.
Other well-established triggers include:
- Isoniazid, an antibiotic used to treat tuberculosis
- Minocycline, a tetracycline antibiotic commonly prescribed for acne
- Quinidine, another heart rhythm medication
These drugs don’t cause lupus as frequently as procainamide or hydralazine, but they appear consistently in case reports and are considered well-documented triggers.
Biologic Medications: TNF Inhibitors
TNF inhibitors are widely prescribed for conditions like rheumatoid arthritis, Crohn’s disease, and psoriasis. Three specific TNF inhibitors are among the most common causes of drug-induced lupus today: etanercept (Enbrel), infliximab (Remicaid), and adalimumab (Humira). Given how many people take these medications, the overall incidence of lupus-like reactions is relatively low, but the sheer number of prescriptions means these cases add up.
TNF inhibitors work by suppressing part of the immune system to control inflammation. Paradoxically, this suppression can trigger a different type of immune overreaction, producing the antibodies and symptoms characteristic of lupus. Symptoms tend to include joint pain and general malaise rather than severe organ involvement.
Cancer Immunotherapy Drugs
Immune checkpoint inhibitors, a class of cancer drugs that unleash the immune system to fight tumors, represent an emerging category of drug-induced lupus triggers. A 2024 pharmacovigilance study using the FDA’s adverse event database found that checkpoint inhibitors overall were associated with a 2.4 times higher reporting rate of lupus-like events compared to other drugs.
The risk was not uniform across the class. Pembrolizumab (Keytruda) showed the strongest signal at 3.45 times the expected rate, followed by nivolumab (Opdivo) at 2.46 times. Drugs targeting PD-1 receptors carried higher risk than those targeting other immune checkpoints. Since 12 checkpoint inhibitors are now FDA-approved and their use in oncology is expanding rapidly, this category is likely to become more prominent.
Less Common but Documented Triggers
A longer list of medications has been linked to drug-induced lupus in smaller numbers of patients. These include:
- Anti-seizure medications (several types)
- Captopril, an ACE inhibitor for blood pressure
- Chlorpromazine, an antipsychotic
- Methyldopa, an older blood pressure medication
- Sulfasalazine, used for inflammatory bowel disease and rheumatoid arthritis
- Hydrochlorothiazide, a common diuretic
- Terbinafine, an antifungal
- Leflunomide, used for rheumatoid arthritis
- Interferons and interleukins, used for various immune and cancer conditions
Levamisole, a veterinary deworming agent that frequently contaminates cocaine, is another documented trigger. This means some people develop lupus-like symptoms not from a prescription at all, but from an adulterant in recreational drugs.
Proton pump inhibitors (PPIs) like omeprazole and lansoprazole have been linked to a skin-specific form of drug-induced lupus called subacute cutaneous lupus. Reported cases of PPI-induced skin lupus increased by 34% between 2009 and 2016, a period during which PPI prescriptions nearly doubled. This form primarily causes rashes rather than joint or organ symptoms.
How Drug-Induced Lupus Differs From Systemic Lupus
Drug-induced lupus generally produces milder disease than the autoimmune form. The most common symptoms are joint pain, muscle aches, fatigue, and sometimes fever or skin rashes. Crucially, it usually spares the kidneys and brain, two organs that systemic lupus frequently damages. This is one of the key ways doctors distinguish between the two conditions.
Blood tests also help. About 75% of people with drug-induced lupus test positive for anti-histone antibodies, which target proteins that package DNA. However, this test alone isn’t definitive because 75% of people with systemic lupus also carry these same antibodies. The clinical picture, the timing relative to starting a medication, and the pattern of organ involvement matter as much as any single lab result.
Why Some People Are More Susceptible
Not everyone who takes a high-risk medication develops lupus symptoms, which points to a genetic component. For drugs like procainamide and hydralazine, the key factor appears to be how quickly your liver processes certain chemicals through a pathway called acetylation. People who are “slow acetylators,” meaning their bodies break down these drugs more slowly, accumulate higher levels of the drug and its byproducts, which increases the chance of triggering an immune reaction. Roughly half of people of European and African descent are slow acetylators, while the trait is less common in people of East Asian descent.
The mechanism varies by drug. Procainamide, chlorpromazine, and quinidine trigger the production of antibodies that target a specific component of DNA packaging called the H2A-H2B dimer. Hydralazine produces antibodies against different targets (H1 and the H3-H4 complex). These distinctions matter mainly to researchers, but the practical takeaway is that different drugs provoke the immune system through different routes, which is one reason the symptom pattern can vary depending on the medication involved.
What Happens After Stopping the Drug
The defining feature of drug-induced lupus is that symptoms improve after the triggering medication is discontinued. Most people notice their joint pain, fatigue, and other symptoms begin to fade within days to weeks of stopping the drug. Antibodies in the blood can take longer to clear, sometimes several months, but they generally decline steadily without additional treatment.
In some cases, symptoms are severe enough to need short-term management while the body recovers, but long-term treatment like what systemic lupus requires is rarely necessary. If symptoms persist well beyond stopping the medication, that raises the question of whether the drug unmasked true systemic lupus rather than causing a purely drug-induced form.